Nycomed Says Phase III Daxas COPD Data Show Drug Is Ready For A Second Shot
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately held European pharma is looking for a U.S. partner to commercialize the potentially first-in-class PDE4 inhibitor.